Curis (NASDAQ:CRIS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Curis (NASDAQ:CRIS) in a research note issued to investors on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price target on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, March 31st.

Curis Stock Performance

Shares of CRIS stock opened at $1.29 on Monday. The stock has a 50 day moving average price of $2.51 and a 200 day moving average price of $3.51. Curis has a 52-week low of $1.02 and a 52-week high of $16.99. The firm has a market capitalization of $10.95 million, a P/E ratio of -0.17 and a beta of 3.51.

Curis (NASDAQ:CRIS) last released its earnings results on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.11. The business had revenue of $2.70 million during the quarter, compared to the consensus estimate of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. As a group, sell-side analysts forecast that Curis will post -7.12 EPS for the current year.

Hedge Funds Weigh In On Curis

A number of large investors have recently added to or reduced their stakes in CRIS. Bleichroeder LP grew its position in shares of Curis by 1,982.2% in the 4th quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock worth $1,593,000 after buying an additional 495,540 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Curis during the 4th quarter valued at $607,000. Samsara BioCapital LLC acquired a new stake in shares of Curis in the 4th quarter worth $607,000. CM Management LLC grew its stake in Curis by 83.3% during the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares during the last quarter. Finally, M28 Capital Management LP increased its position in Curis by 23.5% during the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after buying an additional 99,108 shares in the last quarter. 29.97% of the stock is currently owned by institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.